
Profile
General Information
Metronidazole is a nitroimidazole antibiotic medication used particularly for anaerobic bacteria and protozoa.
Metronidazole 1.3% Vaginal Gel is specifically indicated for the treatment of bacterial vaginosis in non-pregnant women.
Metronidazole 1.3% is supplied as a vaginal gel for topical administration. Metronidazole vaginal gel 1.3% should be administered once intravaginally at bedtime.
Clinical Results
FDA Approval
The FDA approval of Metronidazole vaginal gel 1.3% was based on a phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. Metronidazole 1.3% was compared to MetroGel-Vagina (metronidazole vaginal gel 0.75%). Results showed that the higher concentration Metronidazole 1.3% was well tolerated and efficacious.
Side Effects
Adverse effects associated with the use of Metronidazole vaginal gel 1.3% may include, but are not limited to, the following:
- vulvovaginal candidiasis
- headache
- vulvovaginal pruritus
- nausea
- diarrhea
- dysmenorrhea
Mechanism of Action
Metronidazole is a nitroimidazole antibiotic medication used particularly for anaerobic bacteria and protozoa.
Additional Information
For additional information regarding Metronidazole 1.3% Vaginal Gel or bacterial vaginosis, please visit the Actavis web page.
Approval Date: 2014-04-01
Company Name: Actavis, Inc.